Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 38
Chinese Journal of Hematology ; (12): 293-299, 2022.
Article in Chinese | WPRIM | ID: wpr-929638


Objective: To analyze the influencing factors of iron metabolism assessment in patients with myelodysplastic syndrome. Methods: MRI and/or DECT were used to detect liver and cardiac iron content in 181 patients with MDS, among whom, 41 received regular iron chelation therapy during two examinations. The adjusted ferritin (ASF) , erythropoietin (EPO) , cardiac function, liver transaminase, hepatitis antibody, and peripheral blood T cell polarization were detected and the results of myelofibrosis, splenomegaly, and cyclosporine were collected and comparative analyzed in patients. Results: We observed a positive correlation between liver iron concentration and ASF both in the MRI group and DECT groups (r=0.512 and 0.606, respectively, P<0.001) , only a weak correlation between the heart iron concentration and ASF in the MRI group (r=0.303, P<0.001) , and no significant correlation between cardiac iron concentration and ASF in the DECT group (r=0.231, P=0.053) . Moreover, transfusion dependence in liver and cardiac [MRI group was significantly associated with the concentration of iron in: LIC: (28.370±10.706) mg/g vs (7.593±3.508) mg/g, t=24.30, P<0.001; MIC: 1.81 vs 0.95, z=2.625, P<0.05; DECT group: liver VIC: (4.269±1.258) g/L vs (1.078±0.383) g/L, t=23.14, P<0.001: cardiac VIC: 1.69 vs 0.68, z=3.142, P<0.05]. The concentration of EPO in the severe iron overload group was significantly higher than that in the mild to moderate iron overload group and normal group (P<0.001) . Compared to the low-risk MDS group, the liver iron concentration in patients with MDS with cyclic sideroblasts (MDS-RS) was significantly elevated [DECT group: 3.80 (1.97, 5.51) g/L vs 1.66 (0.67, 2.94) g/L, P=0.004; MRI group: 13.7 (8.1,29.1) mg/g vs 11.6 (7.1,21.1) mg/g, P=0.032]. Factors including age, bone marrow fibrosis, splenomegaly, T cell polarization, use of cyclosporine A, liver aminotransferase, and hepatitis antibody positive had no obvious effect on iron metabolism. Conclusion: There was a positive correlation between liver iron concentration and ASF in patients with MDS, whereas there was no significant correlation between cardiac iron concentration and ASF. Iron metabolism was affected by transfusion dependence, EPO concentration, and RS.

Ferritins , Humans , Iron , Iron Overload , Liver/metabolism , Myelodysplastic Syndromes/therapy , Primary Myelofibrosis , Retrospective Studies , Splenomegaly
Chinese Journal of Hematology ; (12): 247-254, 2022.
Article in Chinese | WPRIM | ID: wpr-929565


Objective: This study aimed to explore the prognostic value of the revised international prognostic scoring system (IPSS-R) and the WHO prognostic scoring system (WPSS) in patients with myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: The clinical data of 184 patients with MDS who received allo-HSCT from July 2016 to June 2019 were retrospectively analyzed. IPSS-R and WPSS were performed at diagnosis and before transplantation. The prognostic values of IPSS-R and WPSS and potential risk factors were explored. Results: With a median follow-up of 21.9 (0.5-47.5) months, the two-year overall survival (OS) and progression-free survival (PFS) rates were (75.1±3.4)% and (71.6±3.6)% , respectively. The two-year cumulative relapse rate and nonrelapse mortality rate were (11.9±0.1)% and (16.5±0.1)% , respectively. There were no significant differences in OS and PFS between the IPSS-R ≤3.5 and >3.5 groups at diagnosis (P=0.409; P=0.724). No significant differences in OS and PFS between the WPSS ≤2 and >2 groups (P=0.426; P=0.726) were observed as well. When the patients were reevaluated before transplantation, the OS and PFS of the IPSS-R ≤3.5 group were significantly better than >3.5 group [OS: (88.6±4.1)% vs (65.8±5.3)% , P=0.003; PFS: (87.6±4.2)% vs (60.5±5.8)% , P=0.002]. However, there were no significant differences in OS and PFS among the WPSS ≤2 and >2 groups (P=0.584; P=0.565). In addition, the OS and PFS of the improved group based on IPSS-R were significantly better than those of the unimproved group before transplantation [OS: (83.8±4.6)% vs (69.3±5.8)% , P=0.027; PFS: (82.8±4.4)% vs. (64.0±7.2)% , P=0.006]. Multivariate analysis indicated that a pretransplant IPSS-R of >3.5 (P=0.021, HR=2.510, 95% CI 1.151-5.476) and TP53 mutation (P=0.047, HR=2.460, 95% CI 1.014-5.971) were independent risk factors for OS, whereas a pretransplant IPSS-R of >3.5 (P=0.017, HR=2.457, 95% CI 1.175-5.141) and pretransplant cytogenetic poor and very poor (P=0.008, HR=2.765, 95% CI 1.305-5.856) were independent risk factors for PFS. Conclusion: A pretransplantation evaluation of IPSS-R could help determine the prognosis of patients with MDS undergoing allo-HSCT. In addition, patients with improved IPSS-R scores before undergoing allo-HSCT had a better prognosis.

Hematopoietic Stem Cell Transplantation , Humans , Myelodysplastic Syndromes/therapy , Prognosis , Retrospective Studies , Risk Factors
Article in Chinese | WPRIM | ID: wpr-928692


OBJECTIVE@#To analyze the clinical characteristics and prognosis of 40 children with myelodysplastic syndrome (MDS), and provide ideas for clinical diagnosis and treatment.@*METHODS@#The clinical characteristics, risk stratification, and different treatment regimens of 40 cases with MDS admitted in Department of Hematology of Children's Hospital of Soochow University from January 1, 2011 to December 31, 2017 was retrospectively analyzed. Kaplan-Meier survival curve were used to estimate 3-year overall survival (OS) rate and event-free survival (EFS) rate.@*RESULTS@#In 40 cases, the ratio of male to female was 1.4∶1.0, male was more than female, and median age was 6.0 years old. Among them, refractory cytopenia (MDS-RCC) was the most common type, and 11 cases were chromosomal abnormalities, 21 cases genetic abnormalities. Fifteen cases accepted hematopoietic stem cell transplantation (HSCT) treatment, while 25 cases did not but drug therapy alone. The 3-year OS rate of the cases who accepted HSCT or not was (72.2±12.2)% and (35.3±10.2)% (P=0.039), 3-year EFS rate was (65.0±12.9)% and (19.2±8.4)% (P=0.012), respectively. Cox regression analysis showed that age < 7 years old (P=0.0333), initial diagnosed platelet < 50×109/L (P=0.007), presence of complex karyotypes and/or gene mutations (P=0.0002), and treatment without HSCT (P=0.016) were the high-risk factors of prognosis. All the children were classified according to IPSS, WPSS and IPSS-R, while analysis result showed that the above three risk assessment had limitations for risk assessment of MDS in children, they could not comprehensively assess the prognosis of children with MDS.@*CONCLUSION@#MDS-RCC in children is more common. Cox multivariate analysis shows that age < 7 years old, initial diagnosed platelet < 50×109/L, presence of complex karyotypes and/or gene mutation, and treatment without HSCT are the high-risk factors of prognosis in children with MDS. HSCT is the most effective treatment to cure children with MDS at present. The current methods such as IPSS-R commonly used in assessment of prognosis in children with MDS show obvious limitation.

Child , Female , Hematopoietic Stem Cell Transplantation , Humans , Male , Myelodysplastic Syndromes/therapy , Prognosis , Retrospective Studies , Treatment Outcome
Article in Chinese | WPRIM | ID: wpr-879845


OBJECTIVE@#To study the clinical features and prognosis of childhood acute myeloid leukemia with myelodysplasia-related changes (AML-MRC).@*METHODS@#A retrospective analysis was performed on the medical data of 14 children who were diagnosed with AML-MRC from June 2014 to March 2020, including clinical features, laboratory examination results, and prognosis.@*RESULTS@#Among the 14 children with AML-MRC, there were 9 boys and 5 girls, with a median age of 11 years (range: 1-17 years), a median leukocyte count of 8.3×10@*CONCLUSIONS@#Childhood AML-MRC is often observed in boys, and AML-M5 is the most common type based on FAB classification. Such children tend to have a poor prognosis. HSCT is expected to improve the poor prognosis of children with AML-MRC. However due to the small number of cases, it is necessary to increase the number of cases for further observation.

Adolescent , Child , Child, Preschool , Female , Hematopoietic Stem Cell Transplantation , Humans , Infant , Leukemia, Myeloid, Acute/therapy , Male , Myelodysplastic Syndromes/therapy , Prognosis , Retrospective Studies
Rev. cuba. hematol. inmunol. hemoter ; 36(3): e1135, jul.-set. 2020. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1156435


Introducción: El comportamiento heterogéneo de los síndromes mielodisplásicos, así como los progresos en los últimos años en el campo de la genética y la biología molecular, han provocado la aparición de múltiples investigaciones con diferentes enfoques terapéuticos. Los agentes hipometilantes son hasta el momento el tratamiento estándar para esta entidad, pero desafortunadamente no son efectivos en el 100 % de los casos y la duración de su respuesta es variable. Objetivo: Analizar las opciones terapéuticas actuales para el tratamiento de los síndromes mielodisplásicos. Métodos: Se realizó una revisión de la literatura, en inglés y español, a través del sitio web PubMed y el motor de búsqueda Google académico de artículos publicados en los últimos 5 años. Se hizo un análisis y resumen de la bibliografía revisada. Análisis y síntesis de la información: Actualmente existen múltiples opciones de tratamiento, la mayor parte dirigidos contra los eventos epigenéticos fundamentales: la hipermetilación, la modificación de las histonas diacetilasa y la activación de la respuesta inmune citotóxica contra clones anormales. Sin embargo, como no se ha establecido una única alteración, los tratamientos en la mayoría de los protocolos se adaptan al riesgo, incluyen un número reducido de casos y los resultados son limitados. Conclusiones: Se considera que una posible solución es dirigir el tratamiento a la alteración específica con base en las alteraciones moleculares y la medicina de precisión, fundamentalmente en los pacientes refractarios o en recaída postratamiento con los actuales agentes hipometilantes(AU)

Introduction: The heterogeneous characteristics of myelodysplastic syndromes, as well as the progress in recent years in the field of genetics and molecular biology, have led to the appearance of multiple investigations with different therapeutic approaches. Hypomethylating agents are so far the standard treatment for this entity, but unfortunately they are not effective in 100% of cases and the duration of their response is variable. Objective: To analyze current therapeutic options for the treatment of myelodysplastic syndromes. Methods: A literature review was carried out, in English and Spanish, through the PubMed website and the Google Scholar search engine, for articles published in the last five years. An analysis and summary of the revised bibliography was carried out. Information analysis and synthesis: Currently, there are multiple treatment options, most of which are directed against fundamental epigenetic events: hypermethylation, modification of histone diacetylase, and activation of the cytotoxic immune response against abnormal clones. However, as long as a single alteration has not been established, treatments, in most protocols, are adapted to risk and include a small number of cases, while their outcomes are limited. Conclusions: It is considered that a possible solution is to direct treatment to specific alteration based on molecular alterations and precision medicine, fundamentally in refractory or relapsed patients after treatment with current hypomethylating agents(AU)

Humans , Male , Female , Myelodysplastic Syndromes/therapy , Epigenomics/methods , Molecular Biology , Precision Medicine
Medicina (B.Aires) ; 79(3): 174-184, June 2019. tab
Article in Spanish | LILACS | ID: biblio-1020055


La Argentina es un país caracterizado por una distribución heterogénea de su población, de sus recursos económicos y, consiguientemente, del acceso a los servicios de salud, lo cual podría afectar el diagnóstico y tratamiento de los pacientes con síndromes mielodisplásicos. Basados en la complejidad creciente para arribar al diagnóstico, estimar el riesgo e indicar un tratamiento adecuado, hemos conducido una encuesta de veintitrés preguntas para evaluar patrones de práctica clínica. El cuestionario se distribuyó entre los 850 hematólogos argentinos inscriptos al XXII Congreso Argentino de Hematología y 195 (22.9%) fueron contestados. El 40.0% refieren que < 75% de sus pacientes acceden al cariotipo, histología de la médula ósea y citometría de flujo. Este acceso disminuye significativamente por una baja cobertura sanitaria (OR 6.3), en población adulta (OR 3.8), al derivar el estudio citogenético (OR 3.2) y fuera del área metropolitana de Buenos Aires (OR 2.4). Los encuestados evitan terminologías oncológicas (77.0%) al introducir el diagnóstico y utilizan el sistema internacional de predicción o su revisión (74.2%) para estadificar riesgo. Sin embargo, éstos priorizan la edad al seleccionar tratamiento y los pediatras indican preferentemente el trasplante de precursores hematopoyéticos. La mayoría de los hematólogos ha prescripto los tratamientos recomendados, cuyas suspensiones se relacionaron con falta de respuesta (62.7%), con participación reducida en ensayos clínicos (8.9%). Por ende, refieren heterogeneidad en el acceso a las herramientas diagnósticas complementarias con diferencias al momento de indicar un tratamiento, dependiendo de la edad de sus pacientes, sin limitaciones aparentes en su prescripción.

Argentina is a country characterized by a heterogeneous distribution of its population, its economic resources and, consequently, access to health services, which could affect the diagnosis and treatment of patients with myelodysplastic syndromes. Based on the increasing complexity to arrive at the diagnosis, estimate the risk and indicate an adequate treatment, we have conducted a survey of twenty-three questions to evaluate patterns of clinical practice. The questionnaire was distributed among 850 hematologists registered at the XXII Argentine Congress of Hematology, and 195 (22.9%) were answered; 40.0% report that < 75% of their patients access the karyotype, bone marrow histology and flow cytometry. This access decreases significantly due to low health coverage (OR 6.3), in the adult population (OR 3.8), when the cytogenetic study is derived (OR 3.2) and outside the metropolitan area of Buenos Aires (OR 2.4). The respondents avoid oncological terminologies (77.0%) when introducing the diagnosis and use the international prediction system or its review (74.2%) to stage risk. However, they prioritize age when selecting treatment and pediatricians preferentially recommend the transplantation of hematopoietic precursors. Most of the haematologists have prescribed the recommended treatments, whose suspensions were related to lack of response (62.7%), with reduced participation in clinical trials (8.9%). Therefore, they report heterogeneity in the access to complementary diagnostic tools with differences at the time of indicating a treatment, depending on the age of their patients without apparent limitations in their prescription.

Humans , Professional Practice , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/therapy , Argentina , Clinical Protocols , Surveys and Questionnaires , Health Surveys
Rev. homeopatia (Säo Paulo) ; 81(3/4): 16-24, 2018. tab, ilus
Article in Spanish | LILACS, HomeoIndex | ID: biblio-969657


As síndromes mielodisplásicas (SMD) representam um grupo heterogêneo de doenças com ampla variação de manifestações clínica e patológicas, que têm em comum um defeito clonal nas células progenitoras (células-tronco). A patogênese da SMD ainda é pouco compreendida, uma vez que há participação de um complexo de eventos abnormais. Neste relato de caso, longitudinal e prospectivo, é apresentado o tratamento de uma paciente diagnosticada com SMD. O acompanhamento e o tratamento desta paciente foi realizado com terapêutica convencional, consistindo em transfusões sanguíneas e quelante de ferro (2003-2015) e tratamento homeopático coadjuvante (2015-2018). Foi constatada retomada da hematopoiese, evoluindo com melhora hematológica sem necessidade transfusional, com consequente suspensão do tratamento com hemotransfusão pela equipe de hematologia, 4 meses depois de iniciar a terapêutica homeopática. (AU)

Myelodysplastic syndrome (MDS) is a heterogeneous group of diseases with variable clinical and pathological manifestations having in common clonal expansion of defective hematopoietic stem cells. The pathogenesis of MDS is still poorly understood, as it involves a complex of abnormal events. In this longitudinal and prospective case report, the homeopathic treatment of a patient diagnosed with MDS is described. The patient received conventional treatment, consisting of blood transfusions and iron chelator (2003-2015) and adjuvant homeopathic treatment (2015-2018). Hematopoiesis returned to normal, and blood transfusions were discontinued by the attending hematology staff 4 months after the onset of homeopathic treatment. (AU)

Humans , Female , Adult , Myelodysplastic Syndromes/therapy , Crotalus horridus/therapeutic use , Ferrum Metallicum/therapeutic use , Phosphorus/therapeutic use , Homeopathy
Bogotá; IETS; mayo 2016. tab, graf.
Monography in Spanish | LILACS, BRISA | ID: biblio-846469


Problema de investigación: Estimar para el caso colombiano, la RICE de lenalidomida más terapia de soporte comparada con terapia de soporte sin lenalidomida para pacientes adultos con SMD y Del 5q en Colombia.Tipo de evaluación económica: Análisis de costo-efectividad (ACE). Población objetivo: Pacientes adultos con SMD y Del 5q en Colombia. Intervención y comparadores: Intervención: lenalidomida (10 mg/día) más terapia de soporte.\r\nHorizonte temporal: Un (1) año. Perspectiva: La perspectiva de análisis es la del Sistema General de Seguridad Social en Salud (SGSSS). Tasa de descuento: No se aplicó tasa de descuento para costos ni para desenlaces en salud debido a que el horizonte temporal es de un año. Estructura del modelo: Para capturar las principales características del SMD y Del 5q se desarrolló un modelo de Markov con probabilidades de transición basadas en el estado de transfusión del paciente, la progresión a LMA y la muerte. La duración del cada ciclo (28 días) se basa en el intervalo de dosificación para lenalidomida. Fuentes de datos de efectividad y seguridad: Los datos de efectividad y seguridad para la elaboración del modelo se obtuvieron del ensayo clínico Fase III MDS-004, el único identificado de este tipo que compara el uso de lenalidomida contra placebo en pacientes con SMD y Del 5q dependientes de transfusión. Desenlaces y valoración: Como unidad natural de desenlace se tomó la proporción de pacientes que alcanzan independencia de transfusión de sangre por un mínimo de 8 semanas consecutivas. Costos incluidos: Se consideran eventos generadores de costos todos los recursos directos asociados al uso de las tecnologías evaluadas. Fuentes de datos de costos: SISMED 2015, Manual de Tarifas ISS 2001 + 30%, Circular No. 02 de 2015 de la Comisión Nacional de Precios de Medicamentos y Dispositivos Médicos, 4 laboratorios clínicos y 2 hemocentros del país. Resultados del caso base: La alternativa de lenalidomida más terapia de soporte es una opción costo-efectiva comparada con la terapia de soporte sin lenalidomida para el tratamiento de SMD y Del 5q en Colombia. \r\nAnálisis de sensibilidad: El análisis de sensibilidad determinístico muestra que los resultados del caso base no son sensibles a variaciones en los costos, aunque cambios en las efectividades pueden alterar esta conclusión. El análisis de sensibilidad probabilístico muestra que, con una probabilidad del 98%, la alternativa de lenalidomida más terapia de soporte sería costo-efectiva para todos los umbrales superiores a $6.345.981,2. Conclusiones y discusión: Es razonable incorporar en el POS la alternativa de lenalidomida más terapia de soporte para el tratamiento de SMD y Del 5q. Esta recomendación obedece a que la tecnología evaluada es costo-efectiva, pero sobre todo a que los pacientes a quienes se les administre esta opción de tratamiento pueden experimentar una mejoría significativa en su calidad de vida.(AU)

Humans , Chromosome Deletion , Myelodysplastic Syndromes/therapy , Thalidomide/analogs & derivatives , Thalidomide/therapeutic use , Biomedical Technology , Colombia , Cost-Benefit Analysis/economics , Health Evaluation/economics
Braz. j. med. biol. res ; 48(10): 871-876, Oct. 2015. tab, ilus
Article in English | LILACS | ID: lil-761603


Treatments for patients with hematologic malignancies not in remission are limited, but a few clinical studies have investigated the effects of salvaged unrelated cord blood transplantation (CBT). We retrospectively studied 19 patients with acute leukemia, 5 with myelodysplastic syndrome (MDS with refractory anemia with excess blasts [RAEB]), and 2 with non-Hodgkin's lymphoma who received 1 CBT unit ≤2 loci human leukocyte antigen (HLA)-mismatched after undergoing myeloablative conditioning regimens between July 2005 and July 2014. All of them were in non-remission before transplantation. The infused total nucleated cell (TNC) dose was 4.07 (range 2.76-6.02)×107/kg and that of CD34+ stem cells was 2.08 (range 0.99-8.65)×105/kg. All patients were engrafted with neutrophils that exceeded 0.5×109/L on median day +17 (range 14-37 days) and had platelet counts of >20×109/L on median day +35 (range 17-70 days). Sixteen patients (61.5%) experienced pre-engraftment syndrome (PES), and six (23.1%) patients progressed to acute graft-versus-host disease (GVHD). The cumulative incidence rates of II-IV acute GVHD and chronic GVHD were 50% and 26.9%, respectively. After a median follow-up of 27 months (range 5-74), 14 patients survived and 3 relapsed. The estimated 2-year overall survival (OS), disease-free survival (DFS), and non-relapse mortality (NRM) rates were 50.5%, 40.3%, and 35.2%, respectively. Salvaged CBT might be a promising modality for treating hematologic malignancies, even in patients with a high leukemia burden.

Adolescent , Adult , Child , Female , Humans , Male , Young Adult , Allografts , Anemia, Refractory, with Excess of Blasts/therapy , Cord Blood Stem Cell Transplantation , Graft vs Host Disease , Leukemia, Biphenotypic, Acute/therapy , Lymphoma, Non-Hodgkin/therapy , Anemia, Refractory, with Excess of Blasts/mortality , Cord Blood Stem Cell Transplantation/mortality , Disease-Free Survival , Follow-Up Studies , Graft vs Host Disease/mortality , Hematologic Neoplasms/mortality , Hematologic Neoplasms/therapy , Leukemia, Biphenotypic, Acute/mortality , Leukemia, Lymphoid/mortality , Leukemia, Lymphoid/therapy , Leukemia, Myeloid/mortality , Leukemia, Myeloid/therapy , Leukemia/mortality , Leukemia/therapy , Lymphoma, Non-Hodgkin/mortality , Myelodysplastic Syndromes/mortality , Myelodysplastic Syndromes/therapy , Retrospective Studies , Remission Induction/methods , Treatment Outcome
Biomédica (Bogotá) ; 35(3): 302-305, jul.-sep. 2015. tab
Article in Spanish | LILACS | ID: lil-765458


Se reporta un caso de bacteriemia recurrente por Bordetella bronchiseptica en un paciente inmunocomprometido con antecedentes de trasplante alogénico de medula ósea por síndrome mielodisplásico, quien ingresó al hospital por síndrome febril. Bordetella bronchiseptica es un agente patógeno veterinario poco común en humanos que afecta principalmente a pacientes inmunocomprometidos y es causa poco frecuente de bacteriemia.

We report a case of recurrent bacteraemia caused by Bordetella bronchiseptica in an immunocompromised patient with a history of allogenic bone marrow transplantation for myelodysplastic syndrome, who was admitted to hospital with febrile syndrome. Bordetella bronchiseptica is an uncommon human pathogen which mainly affects immunocompromised patients, being a rare cause of bacteraemia.

Humans , Male , Middle Aged , Bordetella Infections/microbiology , Opportunistic Infections/microbiology , Bone Marrow Transplantation , Bordetella bronchiseptica/isolation & purification , Bacteremia/microbiology , Recurrence , Myelodysplastic Syndromes/therapy , Bordetella Infections/etiology , Opportunistic Infections/etiology , Immunocompromised Host , Bordetella bronchiseptica/drug effects , Bacteremia/etiology , Pneumonia, Bacterial/etiology , Pneumonia, Bacterial/microbiology , Drug Resistance, Multiple, Bacterial , Allografts , Gastroenteritis/etiology , Gastroenteritis/microbiology , Graft vs Host Disease/drug therapy , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use
Bogotá; IETS; dic. 2014. tab, ilus.
Monography in Spanish | LILACS, BRISA | ID: biblio-847099


Introducción: los síndromes mielodisplásicos (SMD) representan un grupo de neoplasias hematológicas de las células progenitoras hematopoyéticas que comparten características comunes como la presencia de citopenias y un riesgo variable de evolucionar a leucemia mieloblástica aguda (LMA). Se origina a partir de células madre hematopoyéticas con aberraciones genéticas adquiridas, dentro de las cuales se encuentra la deleción aislada del 5q, presente en aproximadamente el 10% de los casos y que se caracteriza por un curso benigno y de bajo riesgo. El objetivo terapéutico en los pacientes con SMD de alto riesgo es modificar la historia natural de la enfermedad y prolongar la supervivencia, y en los pacientes con SMD de bajo riesgo, mejorar la sintomatología y la calidad de vida. Objetivo: evaluar los beneficios y riesgos del uso de lenalidomida para el tratamiento de pacientes con síndrome mielodisplásico y deleción 5q. Metodología: se realizó una búsqueda de evidencia en las bases de datos: MEDLINE, EMBASE, la Librería Cochrane, LILACS, CENTRAL y en el Registro International de ensayos clínicos. Dos evaluadores de manera independiente, tamizaron las referencias obtenidas, resolviendo las discrepancias por consenso. La calidad de los estudios seleccionados fue evaluada empleando la herramienta de riesgo de sesgo de la colaboración Cochrane. Resultados: se identificó un único ensayo clínico aleatorizado, controlado fase 3 y 4 ensayos clínicos fase 2. Se presentan los datos de efectividad y seguridad de la comparación de lenalidomida con placebo, en términos de parámetros de respuesta, supervivencia libre de progresión (SLP), supervivencia global (SG) y eventos adversos. Conclusiones: lenalidomida es un tratamiento efectivo para el manejo de pacientes con síndrome mielodisplásico y deleción 5q. Los eventos adversos más comúnmente relacionados con el uso de este medicamento son neutropenia y trombocitopenia.(AU)

Humans , Chromosome Deletion , Myelodysplastic Syndromes/therapy , Thalidomide/analogs & derivatives , Biomedical Technology , Colombia , Medication Adherence , Reproducibility of Results , Thalidomide/therapeutic use , Treatment Outcome
Article in English | WPRIM | ID: wpr-221307


Many Korean patients with transfusion-induced iron overload experience serious clinical sequelae, including organ damage, and require lifelong chelation therapy. However, due to a lack of compliance and/or unavailability of an appropriate chelator, most patients have not been treated effectively. Deferasirox (DFX), a once-daily oral iron chelator for both adult and pediatric patients with transfusion-induced iron overload, is now available in Korea. The effectiveness of deferasirox in reducing or maintaining body iron has been demonstrated in many studies of patients with a variety of transfusion-induced anemias such as myelodysplastic syndromes, aplastic anemia, and other chronic anemias. The recommended initial daily dose of DFX is 20 mg/kg body weight, taken on an empty stomach at least 30 min before food and serum ferritin levels should be maintained below 1000 ng/mL. To optimize the management of transfusion-induced iron overload, the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) reviewed the general consensus on iron overload and the Korean data on the clinical benefits of iron chelation therapy, and developed a Korean guideline for the treatment of iron overload.

Anemia, Aplastic/therapy , Benzoates/therapeutic use , Blood Transfusion/adverse effects , Chelation Therapy/methods , Humans , Iron Chelating Agents/therapeutic use , Iron Overload/therapy , Myelodysplastic Syndromes/therapy , Pyridones/therapeutic use , Republic of Korea , Triazoles/therapeutic use
Salud(i)ciencia (Impresa) ; 18(8): 751-753, mar. 2012.
Article in Spanish | LILACS | ID: lil-656566


Revisión acerca de los aspectos epidemiológicos locales e internacionales en relación con este grupo heterogéneo de neoplasias hematológicas.

Hematologic Diseases/epidemiology , Hematologic Diseases/therapy , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/epidemiology , Myelodysplastic Syndromes/pathology , Myelodysplastic Syndromes/therapy
Homeopatia Méx ; 79(666): 5-21, mar.-abr. 2010.
Article in Spanish | LILACS | ID: lil-561012


Los Síndromes Mielodisplásicos (MDS) constituyen un grupo de trastornos clonales caracterizados por citopenias progresivas, dishematopoyesis y su riesgo a progresar a leucemia mieloide aguda. La etiología de los MDS primarios es desconocida y los secundarios pueden deberse al uso de agentes antineoplásicos, productos químicos y radio o quimioterapia. Su fisiopatologia incluye la alteración de la hematopoyesis, que puede acompañarse de alteraciones citogenéticas, moleculares e inmunológicas. El diagnóstico es la afectación de al menos el 10% de las células en cada una de las series (dishematopoyesis). En el 80 % de las biopsias de médula ósea se observan signos de desorganización en la arquitectura hematopoyética habitual. En el diagnóstico diferencial están los procesos com alteraciones mielodisplásicas como las anemias por deficiência de vitamina B12, ácido fólico o piridoxina, las hepatopatias crónicas, la anemia de las enfermedades crónicas, el tratamiento con quimioterapia, la infección por VIH y la aplasia medular, entre otros. El tratamiento alopático es tóxico que em pocas ocasiones mejora la calidad de vida, sólo el trasplante de médula ósea. La terapéutica Homeopática, en cambio, estimula y modula la hematopoyesis, logrando así mejoría y em gran cantidad de los pacientes remisión de su estado.

Humans , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/epidemiology , Myelodysplastic Syndromes/prevention & control , Myelodysplastic Syndromes/therapy
Arq. bras. cardiol ; 87(5): e168-e171, nov. 2006. ilus
Article in Portuguese | LILACS | ID: lil-452158


Homem de 61 anos de idade, com diagnóstico de síndrome mielodisplásica e angina instável foi submetido a angiografia coronariana e implante de stent. O hemograma revelou 40.000/mm³ plaquetas. A angiografia coronariana, precedida por transfusão de plaquetas, revelou obstrução de 80 por cento no óstio da artéria coronariana direita (ACD). Após o uso de clopidogrel 75mg, o paciente foi submetido à nova transfusão de plaquetas e a implante de stent LEKTON 3,0x10mm na lesão da ACD. Não ocorreram sangramentos após as retiradas dos introdutores. Após seis meses, o teste de esforço foi positivo e nova angiografia, sob as mesmas condições anteriores, mostrou reestenose intra-stent. Esse relato sugere que o implante de stent coronariano em pacientes com plaquetopenia é seguro, contanto que se realize a transfusão profilática de plaquetas, embora em longo prazo possa haver reestenose.

Sixty-one-year-old male patient with diagnosis of myelodysplastic syndrome and unstable angina was submitted to coronary angiography and implant of stent. His Blood vell count revealed 40,000 platelets/mm³. Coronary angiography with previous platelet transfusion showed obstruction of 80 percent of the right coronary artery (RCA). Following the administration of clopidogrel, the patient was submitted to another platelet transfusion and stent implantation in the RCA lesion. No bleeding was observed after the introducers removal. After 6 months, treadmill test was positive and new coronary aniography, in the same conditions, showed in-stent restenosis. This case report suggests that coronary stent implantation in patients with thrombocytopenia is a safe procedure, provided that prophylactic platelet transfusion is performed, although late restenosis may occur.

Humans , Male , Middle Aged , Angioplasty, Balloon, Coronary , Angina, Unstable/therapy , Myelodysplastic Syndromes/therapy , Stents , Ticlopidine/analogs & derivatives , Angina, Unstable/complications , Angina, Unstable/diagnosis , Coronary Angiography , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/diagnosis , Platelet Transfusion , Platelet Aggregation Inhibitors/therapeutic use , Treatment Outcome
Rev. bras. hematol. hemoter ; 28(3): 218-220, jul.-set. 2006. tab
Article in Portuguese | LILACS | ID: lil-445994


O tratamento do paciente com mielodisplasia deve ser feito considerando o risco biológico da doença, a idade e as condições clínicas do paciente. De um modo geral, uma doença de alto risco necessitaria de um tratamento mais agressivo. Porém, devido à elevada idade mediana no diagnóstico, a maioria dos pacientes não tolera tratamentos intensivos. O transplante de células-tronco hematopoiéticas é a única opção para aqueles que objetivam a cura da doença. Para aqueles que não podem se submeter a um transplante, as opções incluem o uso de quimioterapia intensiva, agentes hipometilantes, tratamento suportivo e/ou inclusão em estudos clínicos. A quimioterapia intensiva semelhante à utilizada para leucemia mielóide aguda é uma boa opção para pacientes em boas condições clínicas e com menos de 65 anos de idade.

To initiate a treatment for myelodysplastic syndrome, the physician should consider the patient's age, status performance and the risk of transformation to acute myeloid leukemia (AML) and death. In theory, a high risk disease should be approached with intense treatment however most patients are not healthy enough to receive aggressive treatment with chemotherapy or stem cell transplantation. For those who are not able to receive a transplantation, the treatment options include AML-like chemotherapy, hypomethylating agents, supportive care alone or participation in a clinical trial. AML-like chemotherapy is still a reasonable choice for those patients who are in good clinical conditions and are younger than 65 years of age.

Humans , Myelodysplastic Syndromes , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/therapy
Pediatr. día ; 22(3): 4-10, jul.-ago. 2006. tab
Article in Spanish | LILACS | ID: lil-443388


Los síndromes mielodisplásticos (SMD) son desórdenes clónales de las células madres hematopoyéticas caracterizados por hematopoyesis inefectiva, citopenia periférica y riesgo variable de transformación a leucemia mieloide aguda (LMA). Los SMD son relativamente raros en niños, representando aproximadamente el 3 por ciento de las neoplasias hematológicas pediátricas. Se han descrito numerosos subtipos de SMD en niños, no existiendo actualmente una clasificación de consenso. Existen desórdenes genéticos que predisponen al desarrollo de SMD en niños, como el síndrome de Down, la neurofibromatosis tipo I y síndrome de falla medular hereditarios; por otro lado, la exposición a agentes quimioterapéuticos y radiaciones ionizantes, aumenta el riesgo de desarrollar SMD tanto en niños como en adultos. Los SMD infantiles usualmente tienen un curso clínico agresivo y son de difícil manejo, siendo el trasplante de médula ósea alogénico el único tratamiento curativo conocido actualmente.

Humans , Child , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/therapy , Diagnosis, Differential , Incidence , Prognosis , Myelodysplastic Syndromes/classification , Myelodysplastic Syndromes/epidemiology , Myelodysplastic Syndromes/etiology , Signs and Symptoms